182 related articles for article (PubMed ID: 31801317)
21. PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages.
Zhu Z; Zhang H; Chen B; Liu X; Zhang S; Zong Z; Gao M
Front Immunol; 2020; 11():588552. PubMed ID: 33329573
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analysis of PD-L1 expression in glioblastoma multiforme.
Heiland DH; Haaker G; Delev D; Mercas B; Masalha W; Heynckes S; Gäbelein A; Pfeifer D; Carro MS; Weyerbrock A; Prinz M; Schnell O
Oncotarget; 2017 Jun; 8(26):42214-42225. PubMed ID: 28178682
[TBL] [Abstract][Full Text] [Related]
23. The role of the PD-1/PD-L1 axis in macrophage differentiation and function during pregnancy.
Zhang Y; Ma L; Hu X; Ji J; Mor G; Liao A
Hum Reprod; 2019 Jan; 34(1):25-36. PubMed ID: 30500923
[TBL] [Abstract][Full Text] [Related]
24. CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma.
Hu ZW; Sun W; Wen YH; Ma RQ; Chen L; Chen WQ; Lei WB; Wen WP
Front Immunol; 2022; 13():952059. PubMed ID: 36045683
[TBL] [Abstract][Full Text] [Related]
25. Plasma PD-L1 as a biomarker in the clinical management of glioblastoma multiforme-a retrospective cohort study.
Masood AB; Batool S; Bhatti SN; Ali A; Valko M; Jomova K; Kuca K
Front Immunol; 2023; 14():1202098. PubMed ID: 37529045
[TBL] [Abstract][Full Text] [Related]
26. Phosphofructokinase 1 platelet isoform induces PD-L1 expression to promote glioblastoma immune evasion.
Wang S; Park SH; Lim JS; Park YY; Du L; Lee JH
Genes Genomics; 2022 Dec; 44(12):1509-1517. PubMed ID: 35917090
[TBL] [Abstract][Full Text] [Related]
27. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G
J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863
[TBL] [Abstract][Full Text] [Related]
28. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419
[TBL] [Abstract][Full Text] [Related]
29. Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
Skinner HD; Giri U; Yang LP; Kumar M; Liu Y; Story MD; Pickering CR; Byers LA; Williams MD; Wang J; Shen L; Yoo SY; Fan YH; Molkentine DP; Beadle BM; Meyn RE; Myers JN; Heymach JV
Clin Cancer Res; 2017 Jun; 23(11):2713-2722. PubMed ID: 28476872
[No Abstract] [Full Text] [Related]
30. Immune micro-environment analysis and establishment of response prediction model for PD-1 blockade immunotherapy in glioblastoma based on transcriptome deconvolution.
Wong D; Yin Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11689-11703. PubMed ID: 37407848
[TBL] [Abstract][Full Text] [Related]
31. Correlation of immune phenotype with IDH mutation in diffuse glioma.
Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
[TBL] [Abstract][Full Text] [Related]
32. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
33. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
34. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
[TBL] [Abstract][Full Text] [Related]
35. Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants.
Saleh R; Toor SM; Al-Ali D; Sasidharan Nair V; Elkord E
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32616706
[TBL] [Abstract][Full Text] [Related]
36. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
37. p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.
Liu J; He D; Cheng L; Huang C; Zhang Y; Rao X; Kong Y; Li C; Zhang Z; Liu J; Jones K; Napier D; Lee EY; Wang C; Liu X
Oncogene; 2020 May; 39(19):3939-3951. PubMed ID: 32203167
[TBL] [Abstract][Full Text] [Related]
38. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
[TBL] [Abstract][Full Text] [Related]
39. Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.
Liu J; Li H; Sun L; Yuan Y; Xing C
Biomed Res Int; 2020; 2020():2496582. PubMed ID: 32596285
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
Devereaux KA; Charu V; Zhao S; Charville GW; Bangs CD; van de Rijn M; Cherry AM; Natkunam Y
Hum Pathol; 2018 Dec; 82():39-45. PubMed ID: 30539796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
